321 related articles for article (PubMed ID: 24251790)
21. Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors.
Álvarez-Reguera C; Prieto-Peña D; Herrero-Morant A; Sánchez-Bilbao L; Batlle-López A; Fernández-Luis S; Paz-Gandiaga N; Blanco R
Eur J Intern Med; 2024 May; 123():102-106. PubMed ID: 38044168
[TBL] [Abstract][Full Text] [Related]
22. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN
Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845
[TBL] [Abstract][Full Text] [Related]
23. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
Quintás-Cardama A
Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
[TBL] [Abstract][Full Text] [Related]
24. Metformin exerts multitarget antileukemia activity in JAK2
Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
[TBL] [Abstract][Full Text] [Related]
25. A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.
Ngo A; Koay AZ; Pecquet C; Diaconu CC; Ould-Amer Y; Huang Q; Kang C; Poulsen A; Lee MA; Jenkins D; Shiau A; Constantinescu SN; Choong ML
Comb Chem High Throughput Screen; 2016; 19(10):824-833. PubMed ID: 27748177
[TBL] [Abstract][Full Text] [Related]
26. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
27. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
28. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
29. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
30. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
Bhagwat N; Koppikar P; Keller M; Marubayashi S; Shank K; Rampal R; Qi J; Kleppe M; Patel HJ; Shah SK; Taldone T; Bradner JE; Chiosis G; Levine RL
Blood; 2014 Mar; 123(13):2075-83. PubMed ID: 24470592
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.
Rai S; Grockowiak E; Hansen N; Luque Paz D; Stoll CB; Hao-Shen H; Mild-Schneider G; Dirnhofer S; Farady CJ; Méndez-Ferrer S; Skoda RC
Nat Commun; 2022 Sep; 13(1):5346. PubMed ID: 36100613
[TBL] [Abstract][Full Text] [Related]
32. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
34. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
[TBL] [Abstract][Full Text] [Related]
35. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.
Griner LN; McGraw KL; Johnson JO; List AF; Reuther GW
Br J Haematol; 2013 Jan; 160(2):177-87. PubMed ID: 23157224
[TBL] [Abstract][Full Text] [Related]
36. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
37. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
39. New JAK2 inhibitors for myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
[TBL] [Abstract][Full Text] [Related]
40. Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.
Saliba J; Hamidi S; Lenglet G; Langlois T; Yin J; Cabagnols X; Secardin L; Legrand C; Galy A; Opolon P; Benyahia B; Solary E; Bernard OA; Chen L; Debili N; Raslova H; Norol F; Vainchenker W; Plo I; Di Stefano A
PLoS One; 2013; 8(9):e74257. PubMed ID: 24066127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
